Quanterix(US:QTRX)2025-08-07 20:30Financial Performance & Outlook - Q2 2025 revenue decreased by 29% to $24.5 million compared to $34.4 million in Q2 2024[17] - GAAP gross margin decreased to 46.2% in Q2 2025 from 64.7% in Q2 2024[17] - The company is aiming for cash flow breakeven in 2026[14] - Full year 2025 revenue guidance is $130 to $135 million, including a $30 million contribution from Spatial[21] - Adjusted cash usage for the full year 2025 is projected to be $34 to $38 million[23] Cost Reduction & Synergies - The company has implemented $64 million of the total $85 million cost reduction plan[15] - Synergy and cost actions are expected to reach $85 million[13] - $3 million cost reduction realized in Q2 2025[14] Strategic Initiatives - The company completed the acquisition of Akoya, enabling new protein biomarker measurements[10, 11] - Strategic investments are being made in new assays, the Simoa One platform, and Alzheimer's diagnostics[12] - The company is building a $100 million high-margin consumables business[13] Alzheimer's Disease Testing - Development of LucentAD multi-marker test for Alzheimer's disease with 90% sensitivity, specificity, and accuracy[16] - Anticipated submission for Single-Site IVD by the end of 2025[16] - Medicare pricing anticipated in 2025 at $897 per test proposed[16]